Radiotherapy and concomitant temozolomide during the first and last weeks in high grade gliomas: long-term analysis of a phase II study.
We tested the efficacy and safety of temozolomide (TMZ) when given concomitantly to radiotherapy only in the first and last weeks of treatment to patients affected by high grade gliomas. Conformal radiotherapy (CTV1: tumor bed + residual tumor if present + 1.5 cm, 5,940 cGy, 180 cGy/day; CTV2: oedema, 3,960 cGy, 180 cGy/day) was associated with TMZ, 75 mg/m(2) x 5 days, the first and last weeks of radiotherapy. Adjuvant chemotherapy with TMZ (150 mg/mq daily x 5 days, q28 on the first cycle, 200 mg/mq daily x 5 days, q28 for the following cycles) was given, after chemoradiation, until disease progression or up to 6 cycles. From October 2000 to December 2003, 29 patients (25 GBL, 86.2%; 4 AA, 13.8%) were enrolled in this study. Twenty-two patients (75.8%) received a median 6 cycles of adjuvant chemotherapy with TMZ (range 1-20). Hematological toxicity was absent during concomitant chemoradiation and mild in adjuvant therapy, while neurological toxicity (seizures) was observed only in one case. At a median follow-up of 66 months (range 3-96), median progression-free survival (PFS) was 8 months, with a 1- and 2-year PFS of 46.7 and 28.7%, respectively; median overall survival (OS) time was 21 months, with a 1- and 2-year OS of 69.2 and 42.3%, respectively. In our experience, TMZ proved to be effective even when given only during the first and the last week of radiotherapy, with lower hematological toxicity.
Balducci
Mario
M
Department of Radiotherapy, Catholic University of the Sacred Heart, Largo A. Gemelli, Rome, Italy.
D'Agostino
Giuseppe Roberto
GR
Manfrida
Stefania
S
De Renzi
Filippo
F
Colicchio
Gabriella
G
Apicella
Giuseppina
G
Mangiola
Annunziato
A
Fiorentino
Alba
A
Frascino
Vincenzo
V
Mantini
Giovanna
G
De Bari
Berardino
B
Pompucci
Angelo
A
Valentini
Vincenzo
V
Anile
Carmelo
C
Cellini
Numa
N
D000328:Adult; D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D003131:Combined Modality Therapy; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy* / Q000532:radiotherapy*; D006801:Humans; D008137:Longitudinal Studies; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D020266:Radiotherapy, Conformal / Q000379:methods*; D000077204:Temozolomide; D016896:Treatment Outcome
D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide
J Natl Cancer Inst. 1993 May 5;85(9):704-10
8478956
Int J Radiat Oncol Biol Phys. 1989 Jun;16(6):1389-96
2542193
Rev Neurol (Paris). 1992;148(6-7):428-34
1448662
Int J Radiat Oncol Biol Phys. 1999 Dec 1;45(5):1175-84
10613310
Cancer. 1993 Apr 15;71(8):2585-97
8453582
Nat Clin Pract Oncol. 2008 Aug;5(8):476-86
18542116
Strahlenther Onkol. 2008 Nov;184(11):572-9
19016015
J Neurosurg. 2001 Aug;95(2):190-8
11780887
Cancer. 2004 Nov 1;101(9):2098-105
15389472
J Clin Neurosci. 2006 Jan;13(1):18-22
16356721
Cancer Res. 2001 Mar 1;61(5):1957-63
11280752
J Clin Oncol. 2003 Apr 15;21(8):1485-91
12697871
N Engl J Med. 2008 Jul 31;359(5):492-507
18669428
J Neurooncol. 2004 Mar-Apr;67(1-2):77-81
15072451
J Neurosurg. 1989 Jul;71(1):1-9
2661738
N Engl J Med. 2001 Jan 11;344(2):114-23
11150363
Anticancer Drugs. 1997 Jan;8(1):92-7
9147618
Cancer. 1983 May 15;51(10):1826-9
6831348
J Clin Oncol. 1998 Dec;16(12):3851-7
9850030
Radiother Oncol. 2002 Sep;64(3):259-73
12242114
Clin Oncol (R Coll Radiol). 2009 Feb;21(1):19-22
18838255
Anticancer Res. 2003 Nov-Dec;23(6D):5159-64
14981983
Strahlenther Onkol. 2005 Mar;181(3):157-63
15756519
Lancet. 2002 Mar 23;359(9311):1011-8
11937180
Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):987-92
17967509
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
10655437
Int J Radiat Oncol Biol Phys. 2008 Jul 15;71(4):999-1005
18258384
Neurol Clin. 2007 Nov;25(4):975-1003, viii-ix
17964023
Cancer Treat Rep. 1983 Feb;67(2):121-32
6337710
Br J Cancer. 2000 Apr;82(8):1371-80
10780513
Br J Cancer. 2006 Nov 6;95(9):1155-60
17024124
N Engl J Med. 2005 Mar 10;352(10):987-96
15758009
Gynecol Oncol. 2000 Sep;78(3 Pt 1):324-8
10985888
Cancer. 1980 Apr 15;45(8):2220-4
7370963